Vapor

Vapor Biotherapeutics is a preclinical-stage biotechnology company developing a novel platform for the targeted delivery of therapeutic proteins directly into the tumor microenvironment. Utilizing its proprietary Viral-Assisted Protein Overexpression and Release (VAPOR) technology, the company employs a modified, non-pathogenic parainfluenza virus (PIV5) to serve as a vehicle for high-level protein production within cancer cells. This approach aims to overcome the limitations of systemic protein delivery, such as toxicity and poor penetration, by ensuring localized and sustained therapeutic action. The company's pipeline is primarily focused on oncology, targeting various solid tumors with engineered viral vectors that can deliver a variety of payloads, including cytokines and antibodies.